4.7 Article

Metabolomic Approach to Screening Homozygotes in Chinese Patients with Severe Familial Hypercholesterolemia

Related references

Note: Only part of the references are listed.
Article Medicine, General & Internal

Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study

Tycho R. Tromp et al.

Summary: Patients with homozygous familial hypercholesterolaemia (HoFH) globally face issues of late diagnosis, under-treatment, and high risk of premature ASCVD. The use of multiple lipid-lowering therapy regimens is associated with lower LDL cholesterol levels and better outcomes. Significant global disparities exist in treatment regimens, control of LDL cholesterol levels, and cardiovascular event-free survival.

LANCET (2022)

Article Pharmacology & Pharmacy

Homozygous familial hypercholesterolemia in China: Genetic and clinical characteristics from a real-world, multi-center, cohort study

Long Jiang et al.

Summary: This study investigated the characteristics of homozygous familial hypercholesterolemia (HoFH) probands from mainland China. The results showed that HoFH has devastating consequences and patients are often diagnosed after years of severely elevated LDL-C levels. Systematic screening and early intensive treatment are essential for these young individuals with HoFH.

JOURNAL OF CLINICAL LIPIDOLOGY (2022)

Article Multidisciplinary Sciences

Low-density lipoprotein receptor genotypes modify the sera metabolome of patients with homozygous familial hypercholesterolemia

Zhiyong Du et al.

Summary: This study reveals the impact of LDLR genotypes on the metabolome of HoFH patients. Patients carrying one or two null mutations showed significant changes in clinical laboratory lipids and serum metabolites compared to defective/defective mutation carriers. The findings suggest that these altered metabolites may serve as potential targets to mitigate the deleterious impact of LDLR mutations on HoFH.

ISCIENCE (2022)

Article Gastroenterology & Hepatology

Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites

Xiang Zhang et al.

Summary: High dietary cholesterol leads to sequential progression of steatosis, steatohepatitis, fibrosis and eventually HCC in mice, concomitant with insulin resistance. Cholesterol-induced NAFLD-HCC formation is associated with gut microbiota dysbiosis, with specific bacterial composition changes between stages of liver disease. Alterations in gut bacterial metabolites were also observed with dietary cholesterol intake. Therapies targeting cholesterol and gut microbiota may be effective for preventing NAFLD-HCC.
Article Cardiac & Cardiovascular Systems

Familial Hypercholesterolemia JACC Focus Seminar 4/4

Julia Brandts et al.

Summary: Early detection of FH and normalization of LDL cholesterol levels are crucial for preventing cardiovascular disease. Various treatments targeting LDL receptor-dependent and independent pathways can be used to manage FH effectively.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)

Article Medicine, Research & Experimental

Pharmacokinetics/pharmacometabolomics-pharmacodynamics reveals the synergistic mechanism of a multicomponent herbal formula, Baoyuan decoction against cardiac hypertrophy

Zhiyong Du et al.

Summary: This study utilized PK/PM-PD and multivariate biological correlation network strategy to investigate the active components and synergistic mechanisms of Baoyuan decoction (BYD) against cardiac hypertrophy (CH). The results revealed that bioavailable BYD-compounds, such as saponins and flavonoids, showed positive or negative correlations with various CH-altered metabolites and PD-indicators during treatment.

BIOMEDICINE & PHARMACOTHERAPY (2021)

Article Biotechnology & Applied Microbiology

Integrated analysis of microRNA and mRNA expression profiles in homozygous familial hypercholesterolemia patients and validation of atherosclerosis associated critical regulatory network

Yue Wu et al.

Summary: This study conducted integrated analysis of transcriptome and miRNA expression profiles in HoFH patients, identifying six differentially expressed miRNAs/genes related to atherosclerosis in HoFH, indicating that the miRNA-mRNA regulatory network may play a critical role in the acceleration of ASCVD in HoFH.

GENOMICS (2021)

Article Pharmacology & Pharmacy

Beyond Lipoprotein(a) plasma measurements: Lipoprotein(a) and inflammation

Gissette Reyes-Soffer et al.

Summary: Genome-wide association, epidemiological, and clinical studies have shown high Lp(a) to be a causal risk factor for ASCVD, largely determined by genetics. Its link to CVD may be driven by pro-inflammatory effects, particularly its association with oxPL and inflammation. Therapies targeting apo(a) to reduce Lp(a) levels are in clinical trials to assess their impact on cardiovascular outcomes.

PHARMACOLOGICAL RESEARCH (2021)

Article Cardiac & Cardiovascular Systems

The Added Value of Coronary Calcium Score in Predicting Cardiovascular Events in Familial Hypercholesterolemia

Antonio Gallo et al.

Summary: The study demonstrated the additional contribution of coronary artery calcium (CAC) score in improving cardiovascular risk stratification and ASCVD prediction in patients with statin-treated HeFH.

JACC-CARDIOVASCULAR IMAGING (2021)

Article Cardiac & Cardiovascular Systems

Limited-Variant Screening vs Comprehensive Genetic Testing for Familial Hypercholesterolemia Diagnosis

Amy C. Sturm et al.

Summary: Comprehensive genetic testing for clinically significant variants associated with familial hypercholesterolemia is more accurate compared to limited-variant screens based on arrays. Limited-variant screens may falsely reassure the majority of individuals at risk for FH, especially those of self-reported Black/African American and Hispanic ancestry, by potentially missing a significant number of pathogenic variants.

JAMA CARDIOLOGY (2021)

Article Medicine, General & Internal

Comparison of Untargeted Metabolomic Profiling vs Traditional Metabolic Screening to Identify Inborn Errors of Metabolism

Ning Liu et al.

Summary: The study compared the diagnostic rates of traditional metabolic screening and clinical metabolomics, finding that clinical metabolomics had a higher diagnostic rate and could identify a wider variety of inborn errors of metabolism.

JAMA NETWORK OPEN (2021)

Article Biochemistry & Molecular Biology

Untargeted Metabolomics for Metabolic Diagnostic Screening with Automated Data Interpretation Using a Knowledge-Based Algorithm

Hanneke A. Haijes et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

Review Cardiac & Cardiovascular Systems

Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care

Gerald F. Watts et al.

NATURE REVIEWS CARDIOLOGY (2020)

Article Cardiac & Cardiovascular Systems

Worldwide Prevalence of Familial Hypercholesterolemia Meta-Analyses of 11 Million Subjects

Sabina O. Beheshti et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)

Article Cardiac & Cardiovascular Systems

Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia The ODYSSEY HoFH Trial

Dirk J. Blom et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)

Article Medicine, General & Internal

Evinacumab for Homozygous Familial Hypercholesterolemia

Frederick J. Raal et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Article Medical Laboratory Technology

Precision of a Clinical Metabolomics Profiling Platform for Use in the Identification of Inborn Errors of Metabolism

Lisa Ford et al.

JOURNAL OF APPLIED LABORATORY MEDICINE (2020)

Review Biochemistry & Molecular Biology

Inborn Errors of Metabolism in the Era of Untargeted Metabolomics and Lipidomics

Israa T. Ismail et al.

METABOLITES (2019)

Review Biochemistry & Molecular Biology

Current status of familial hypercholesterolemia in Chinese populations

Brian Tomlinson et al.

CURRENT OPINION IN LIPIDOLOGY (2019)

Review Biochemistry & Molecular Biology

Cholesterol and bile acid-mediated regulation of autophagy in fatty liver diseases and atherosclerosis

Yifeng Wang et al.

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2018)

Review Endocrinology & Metabolism

Role of Bile Acids in Metabolic Control

Antonio Molinaro et al.

TRENDS IN ENDOCRINOLOGY AND METABOLISM (2018)

Article Medicine, General & Internal

Familial hypercholesterolaemia

Joep C. Defesche et al.

NATURE REVIEWS DISEASE PRIMERS (2017)

Article Cardiac & Cardiovascular Systems

Analysis of LDLR variants from homozygous FH patients carrying multiple mutations in the LDLR gene

Long Jiang et al.

ATHEROSCLEROSIS (2017)

Article Cardiac & Cardiovascular Systems

The genetic spectrum of familial hypercholesterolemia in the central south region of China

Rong Xiang et al.

ATHEROSCLEROSIS (2017)

Review Cell Biology

A Next Generation Multiscale View of Inborn Errors of Metabolism

Carmen A. Argmann et al.

CELL METABOLISM (2016)

Editorial Material Cardiac & Cardiovascular Systems

Heterozygous Familial Hypercholesterolemia

Angela Onorato et al.

CIRCULATION (2016)

Review Biochemistry & Molecular Biology

Clinical Metabolomics: The New Metabolic Window for Inborn Errors of Metabolism Investigations in the Post-Genomic Era

Abdellah Tebani et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)

Review Cardiac & Cardiovascular Systems

Management of patients with familial hypercholesterolaemia

Zeljko Reiner

NATURE REVIEWS CARDIOLOGY (2015)

Review Biotechnology & Applied Microbiology

Targeting bile-acid signalling for metabolic diseases

Charles Thomas et al.

NATURE REVIEWS DRUG DISCOVERY (2008)